Skip to content

A comparative clinical trial to study effects of the difference between the naga shalaka and glass rod shalaka with rasanjana in patients with blepharitis

A Randomized Comparative Clinical Study Between Naga Anjana Shalaka and Glass Rod Shalaka with Rasanjana in the management of Praklinna Vartma with reference to Blepharitis - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057498
Enrollment
106
Registered
2023-09-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H010- Blepharitis

Interventions

None listed

Sponsors

Shri Dharmasthala Manjunatheshwara Institute of Ayurveda and Hospital Bangalore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of all occupation. Patient Age group above 10 years and below 60 years of Age. Irrespective of Gender and Religion. Patient having signs and symptoms of Praklinna Vartma

Exclusion criteria

Exclusion criteria: Patients having diseases like corneal ulcer, ectropion, entropion, trichiasis, dacryocystitis, dry eye, lagophthalmous, acute chronic infective conjunctivitis etc. Patients suffering from specific eyelid disorders like tumor, carcinoma. Patients with other systemic disorders which may interfere with the course of study

Design outcomes

Primary

MeasureTime frame
improvement in subjective parameter - manda ruja, bahyatama shunam, antaha klinnam, bulbar congestion, srava, shota, kandu, nisthodha objective parameter - pictorial presentation schirmers testTimepoint: 21 days after 1st follow up

Secondary

MeasureTime frame
sustained effect of treatment after follow upTimepoint: 3 weeks

Countries

India

Contacts

Public ContactDr. Chandana P

AYURVED MAHAVIDYALAYA SION MUMBAI

ravimore67@gmail.com9967483930

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026